Three commonly used isolates of murine prions, 79A, 139A, and RML, were derived from the so-called Chandler isolate, which was obtained by propagating prions from scrapie-infected goat brain in mice. RML is widely believed to be identical with 139A; however, using the extended cell panel assay (ECPA), we here show that 139A and RML isolates are distinct, while 79A and RML could not be distinguished. We undertook to clone 79A and 139A prions by endpoint dilution in murine neuroblastoma-derived PK1 cells. Cloned 79A prions, when returned to mouse brain, were unchanged and indistinguishable from RML by ECPA. However, 139A-derived clones, when returned to brain, yielded prions distinct from 139A and similar to 79A and RML. Thus, when 139A prions were transferred to PK1 cells, 79A/RML-like prions, either present as a minor component in the brain 139A population or generated by mutation in the cells, were selected and, after being returned to brain, were the major if not only component of the population.
Concentrated CM.
Prions secreted by infected cells were recovered from conditioned medium (CM). It has been previously shown that the CPA results obtained with prions from cell lysates and those obtained with prions from CM are similar (see supporting online material in reference 15). CM was cleared at 500 ϫ g for 5 min, and prions were ultracentrifuged for 2 h onto a 10-ml sucrose cushion (20% sucrose [wt/wt] in 1ϫ TNE buffer [25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA]), in a Ti45 rotor (Beckman Coulter) at 35,000 rpm and 4°C. The resulting pellet was suspended in OBGS to a 100ϫ to 300ϫ concentration of the original volume.
SSCA. Typically, six serial 1:5 dilutions of the prion preparation (brain homogenate or concentrated conditioned medium) were added in triplicate to 96-well plates and 5,000 cells were added to each well. Triplicate wells with uninfected cells served as background control; another set of triplicates contained the highest concentration of inoculum used and 10 g pentosan polysulfate/ml (Bene PharmaChem GmbH & Co. KG, Geretsried, Germany) to inhibit prion replication (3) and to assess the possible persistence of the inoculum. After 4 days, the cells were split 1:5 to 1:8, depending on their growth rate. After reaching confluence following the third split, 20,000 cells/well were transferred into wells of preactivated Multiscreen IP 96-well 0.45-m filter plates (Millipore). Supernatants were drained by vacuum, the plates were dried at 50°C for at least 1 h, and the samples were subjected to the PK-enzyme-linked immunosorbent spot (ELISPOT) assay directly or after storage at 4°C.
PK-ELISPOT assay. Samples were incubated for 90 min at 37°C with 70 l of 1 g proteinase K (Roche)/ml lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.5% Triton X-100). All further steps were carried out at room temperature. The samples were washed twice with PBS and denatured with 120 l of 3 M guanidinium thiocyanate in 10 mM Tris-HCl, pH 8.0, for 10 min. After four washes with distilled water (dH 2 O), samples were incubated for 1 h with 0.5% nonfat dry milk in TBS (10 mM Tris-HCl, pH 8.0, 150 mM NaCl), followed by 1 h of incubation with 70 l of 0.7 g humanized anti-PrP antibody D18 (22)/ml of 1% nonfat dry milk in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20) . After four washes with TBST, 70 l of alkaline phosphatase (AP)-conjugated anti-IgG (1:5,000; Southern Biotechnology Associates, Birmingham, AL) in 0.5% nonfat dry milk in TBST was applied for 1 h. Wells were washed four times with TBST. Then, the whole plate was immersed once in TBS and dried. Signals were visualized with the AP conjugate substrate kit (Bio-Rad), and PrP res -positive cells ("spots") were counted using the Bioreader 5000-Eb cytometer (BioSys).
ECPA. Prion strains can be distinguished by their specific ability to infect a panel of different cell lines, as monitored by the SSCA (17) . Prion- ). The cells were propagated for about 50 doublings, and PrP res -positive cells were determined by the PK-ELISPOT assay. b Wells giving spot numbers of Ͼ (background plus 5 SDs) were scored as positive. The probability that a well was infected by more than one prion,
where m is the average number of prions/well and P n is the probability of n prions/well. c P (0) ϭ 1 Ϫ (positive wells/total wells). d m ϭ ln[1/P (0) ] ϭ average number of prions/well. e m C ϭ m/100 ϭ average number of prions/cell. and cell line-specific inhibitors like swainsonine, kifunensine, or castanospermine (1) complement and extend the original panel of cell lines. In the work described here, the ECPA includes CAD cells, LD9 cells, R33 2H11 cells, and PK1 cells, as well as PK1 cells in the constant presence of swainsonine (1 g/ml) or kifunensine (5 g/ml). The cells' response to prions is determined by the response index (RI), the reciprocal of the dilution required to yield a certain number of positive cells (spots) per 20,000 cells. The ratio of RIs is characteristic for different prion strains (Table 1) . For calculating statistics, the log values of the RIs and their ratios were used.
Endpoint dilution cloning in cell culture. PK1 cells were seeded at 100 cells/well in 96-well plates and inoculated with highly diluted 79A-or 139A-infected brain homogenates (final concentration, 10 Ϫ9 and 5 ϫ 10 Ϫ10 ). The cells were repeatedly grown to confluence and split three times 1:3 followed by eight 1:10 splits; after a total of about 50 doublings, 20,000 cells from each well were subjected to the PK-ELISPOT assay and samples containing PrP res -positive cells (spot numbers Ͼ [background plus 5 standard deviations {SDs}]) were scored as positive. The probability that under the conditions chosen a well was infected by more than one prion, P (n Ͼ 1) ϭ 1 Ϫ e Ϫm (1 ϩ m), where P n is the probability of finding n prions/well and m is the average number of prions/well, was 10 Ϫ3 or less, as shown in Table 2 . Five 79A or 139A prion clones were expanded; conditioned media were harvested, concentrated, and inoculated into C57BL/6 mice. The brain homogenates from terminally ill mice were characterized by ECPA. For comparison, uncloned PK1[139A] prions were prepared by inoculating PK1 cells seeded at either 100 cells/well or 5,000 cells/well with low dilutions of 139A brain homogenate (final concentrations, 5 ϫ 10 Ϫ5 and 4 ϫ 10 Ϫ5 , respectively). After about 50 and 14 cell doublings, respectively, three distinct populations were expanded, concentrated conditioned medium was inoculated into mice, and the brains were processed as described above.
Infectivity determination by SSCA. Infectivity determinations were performed by SSCA on CAD cells, relative to control brain homogenate, whose titer was determined by the mouse bioassay (18) .
Western blot analysis. To detect PrP res by Western blot analysis, samples (3 mg total protein/ml in PBS, 0.5% Triton X-100) were digested with 25 g proteinase K (Roche)/ml at 37°C for 1 h. Undigested controls were run in parallel. The digestion was stopped with 20 l phenylmethylsulfonyl fluoride (PMSF) (100 mM)/ml, and the samples were denatured by being boiled in XT-MES sample buffer (Bio-Rad) at 100°C for 10 min. Electrophoretic separation (4 to 12% Criterion gel; Bio-Rad) and wet transfer (Bio-Rad) to polyvinylidene difluoride (PVDF) Immobilon membranes (Millipore) were performed by standard procedures. All further procedures were done at room temperature. Membranes were incubated for 1 h in blocking solution (5% nonfat dry milk in PBST [PBS, 0.1% Tween 20] ) and immunostained with 0.7 g humanized anti-PrP antibody D18 (22)/ml in 1% nonfat dry milk in PBST, followed by three washes with PBST and 1 h of incubation with horseradish peroxidase (HRP)-conjugated anti-IgG antibody (Southern Biotechnology Associ- ates, Birmingham, AL; 1:15,000 in 0.5% nonfat dry milk in PBST). After three washes with PBST, chemiluminescence was induced by ECL-Plus (Pierce) and recorded by charge-coupled device (CCD) imaging (BioSpectrum AC Imaging System; UVP).
RESULTS
Many murine prion strains used in laboratories throughout the world were cloned by endpoint dilution in mice at the Neuropathogenesis Unit of the Institute for Animal Health (NPU). In this procedure, mice are injected with prion preparations diluted to the extent that only 1 in 10 or more mice becomes infected, and this procedure is repeated once or twice more. The strains 79A and 139A were derived from the so-called Chandler isolate, which originated from scrapie-infected goats; 79A, but not the 139A that we used, had been cloned at the NPU in Edinburgh, United Kingdom (H. Baybutt, personal communication). RML was also derived from the Chandler isolate and propagated for many decades in the Rocky Mountain Laboratory but was never cloned. There are contradictory opinions as to whether or not RML is similar or identical to 79A or 139A; several authors consider RML similar to or identical with 139A (11, 19) , while Tremblay et al. (20) found different PrP res brain deposition patterns for these two strains. We compared RML, 139A, and 79A prions by the ECPA and found that, as described earlier (17), all three strains could chronically infect CAD, PK1, and LD9 cells but not R33 2H11 cells. However, swainsonine (1 g/ml) and kifunensine (5 g/ml) strongly inhibited chronic infection of PK1 cells by both RML and 79A prions, while infection by 139A was less inhibited by swainsonine and almost unaffected by kifunensine ( Fig. 1; Table 1 ). Thus, 139A and RML are clearly different, while 79A and RML were indistinguishable by the criteria that we used.
We next undertook to clone 79A and 139A by endpoint dilution in cultured cells rather than in mice. PK1 cells were distrib- Table 5 for details. ns, not significant. uted into 96-well plates at 100 cells/well, infected with 79A or 139A brain homogenate at a high dilution (10 Ϫ9 or 5 ϫ 10 Ϫ10 ), and propagated for about 50 doublings, and the individual wells were assayed by PK-ELISPOT assay. Table 2 shows that the average number of prions per cell in the various experiments ranged from 0.65 ϫ 10 Ϫ4 to 4.7 ϫ 10 Ϫ4 and that the probability that a well was infected by more than one prion was between 10 Ϫ3 and 10 Ϫ4 for 79A and between 10 Ϫ3 and 10 Ϫ5 for 139A. C57BL/6 mice inoculated intracerebrally (i.c.) with concentrated conditioned medium of 79A-or 139A-infected PK1 clones (designated PK1[79A] and PK1[139A], respectively) ( Table 3 ) succumbed to scrapie disease with the symptoms usually seen in animals infected with RML, 79A, or 139A (see Materials and Methods). The ECPA patterns of brain homogenates from mice inoculated with original brain-derived C57[79A] and from mice inoculated with PK1[79A]-derived prion populations were indistinguishable ( Fig. 1 and Tables 1 and 4) Fig. 1 and 2 ; Tables 1, 4 , and 5). Thus, the 139A prions that had been cloned in PK1 cells and subsequently propagated in brain differed from the original 139A prions and resembled brain-derived RML or 79A prions. To ascertain whether the clones that we picked might have been aberrant, we infected PK1 cells with high multiplicities of C57[139A] prions, expanded three distinct cell populations, and inoculated four mice each with conditioned media of the resulting prion populations (Table 3) . As in the first experiment, the C57/PK1[139A] prions resembled RML or 79A prions and not 139A prions ( Fig.  2B and Table 5 ).
DISCUSSION
The ECPA clearly shows that RML and 139A strains are distinct entities but does not distinguish between RML and 79A, which may be the same or not. In view of our finding that 139A prions switch to a strain indistinguishable from 79A or RML when passaged through PK1 cells and returned to mouse brain, it seems probable that the Chandler sample transferred to the Rocky Mountain Laboratory-whatever it originally contained-ended up consisting of 79A prions, either because these were selected from a mixture of 79A and 139A or because 139A converted to 79A in the course of multiple vertical transfers. Conversion of 139A to 79A has been mentioned, but the details are not accessible to us (6) , as quoted in references 12 and 8; Dickinson and Outram considered "139A" a mixture of strains (7) . Although 139A has been cloned by endpoint dilution in mice (13) , the sample that we obtained was uncloned.
It was recognized early on that prion strains can adapt to new hosts as a consequence of mutation and selection (2, 12, 13) , mutation at that time being considered a change in the nucleic acid sequence of a virus-like entity, rather than a conformational change of PrP Sc , as it is now (4, 21) . More recently, it was shown that prions can undergo adaptation even when transferred from one cell type to another within the same species (15, 18, 21) . Thus, when 22L prions were transferred from brain to PK1 cells, they gradually changed their properties, losing their ability to infect R33 cells and becoming sensitive to inhibition by swainsonine; these changes were reversed when the prions were returned to brain (15, 16, 18) . We believe that prion populations are quasispecies (9, 10), consisting of a multitude of variants, the ones fittest for a particular environment predominating (4, 15, 21) , and we have shown that variants arise in cloned prion populations in the course of propagation (15, 16, 18) , explaining how quasispecies arise.
Why would 139A propagate stably in brain but, after being passaged through PK1 cells and returned to brain, propagate stably as 79A/RML-like prions? We consider two possibilities. (i) The 139A population contains low levels of 79A/RML prions, which, upon transfer to PK1 cells, are selected to the exclusion of 139A Fig. 2A) . c "Authentic" brain-derived C57[139A] prions were compared to C57/PK1[139A] prions, either cloned in PK1 cells by endpoint dilution and returned to brain or propagated as uncloned whole population (wp) in PK1 cells and then returned to brain. Calculations were performed as described above. The inhibitory effects of swainsonine on the prion replication in PK1 cells are the same for cloned and uncloned C57/PK1[139A] prions, but they are significantly different from those for C57[139A] prions (Fig. 2B). prions. (ii) The 139A population propagates stably in brain because it neither contains 79A/RML contaminants nor gives rise to them by mutation; however, while mutation from 139A to 79A/ RML-like prions in brain may be precluded by an insurmountable free energy barrier, this can be overcome in PK1 cells, where 79A/ RML-like prions can arise and be selected. In either case, PK1 cells would provide a potent selection of 79A/RML-like prions over 139A prions.
Conversion of 79A to 139A prions in mouse brain has not been described in the literature and may not occur, either because the free energy barrier is too high or because any 139A arising is outcompeted by 79A.
As mentioned above, 22L prions adapt to cells but, when returned to brain, give rise to prions indistinguishable from the original 22L (15, 18) . An important conclusion from the work reported here is that transfer of prions from brain to a cell line and back can also result in a permanent strain change, so that the attractive strategy of endpoint cloning of prion strains in cells is not a viable option.
